EGFR and neoplasm: Although this and further data for the tetramers such as in vivo therapeutic studies and biodistribution are needed in future work, the present study demonstrated that h528 scFv tetramer has a stable structure, high inhibitory effect on tumor cell growth, and long blood retention time, and is therefore an attractive, low‐cost candidate next‐generation anti‐EGFR therapeutic antibody.